1 (587) 885 3158 clinic@magiccalgary.ca

Clinical Trials

Our clinical trials units is dedicated to providing access to research therapies for rare metabolic and genetic diseases

Fabry Disease Studies

Peridot

A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults with Fabry Disease who are Treatment-naïve or Untreated for At least 6 Months

Click here for more information

Fabry HCM

Screening for Fabry Cardiomyopathy Using Cardiac Magnetic Resonance Imaging

Migalastat SWITCH

Evaluation of biomarkers for patients receiving Migalastat after switching from ERT

Gaucher, Fabry, MPS I, and Pompe Registries

Rare disease registries for lysosomal storage disorders

CFDI

Canadian Fabry Disease Initiative Registry

GRIT STUDY

M.A.G.I.C. Clinic, the largest metabolic diseases clinic in Alberta, Canada is looking to learn better ways of managing virtual care for rare disease patients worldwide.

Pompe Disease Studies

Gaucher, Fabry, MPS I, and Pompe Registries

Rare disease registries for lysosomal storage disorders

GRIT STUDY

M.A.G.I.C. Clinic, the largest metabolic diseases clinic in Alberta, Canada is looking to learn better ways of managing virtual care for rare disease patients worldwide.

Gaucher Disease Studies

Gaucher, Fabry, MPS I, and Pompe Registries

Rare disease registries for lysosomal storage disorders

GRIT STUDY

M.A.G.I.C. Clinic, the largest metabolic diseases clinic in Alberta, Canada is looking to learn better ways of managing virtual care for rare disease patients worldwide.

AVRO-RD-02-LTF01

A FOLLOW-UP STUDY OF SUBJECTS WITH TYPE 1 GAUCHER DISEASE WHO PREVIOUSLY RECEIVED AVR-RD-02 GENE THERAPY.

More Studies

CMVibe Trial

A Phase 1/2a Open-Label Dose-Ranging and Observer-Blind Placebo-Controlled, Safety and Immunogenicity Study of mRNA-1647 Cytomegalovirus Vaccine in Female and Male Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age.

Click here to request more information

PALomino

A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding

Click here to request more information

PTC923-MD-003-PKU

A PHASE 3 STUDY OF PTC923 IN SUBJECTS WITH
PHENYLKETONURIA

GRIT STUDY

M.A.G.I.C. Clinic, the largest metabolic diseases clinic in Alberta, Canada is looking to learn better ways of managing virtual care for rare disease patients worldwide.

REN001

A DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF 24 WEEKS TREATMENT WITH REN001 IN
PATIENTS WITH PRIMARY MITOCHONDRIAL MYOPATHY (PMM)

Gene Therapy Trials

ST-920-201

Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease

Click here for more information

GTX-102

A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)

Click here for more information

juMPStart study

A Phase 1 Open-Label Dose Escalation Study to Evaluate the
Safety and Efficacy of HMI-203 in ERT-Treated Adults with
Mucopolysaccharidosis Type II (MPS II)

Click here for more information

View Promotional Video

FACTS

Phase I Gene Therapy for Fabry Disease

© Copyright 2019
M.A.G.I.C Clinic
All Rights Reserved

Contact Us:

P: +1 (587) 885-3158
F: +1 (866) 566-7683

clinic@magiccalgary.ca

215 – 971 64 Ave NE, Calgary, Alberta, Canada, T2E 7Z4

Follow us On Social Media: